IsoRay's Proprietary Cesium-131 Product Line Will Be on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
IsoRay's Proprietary Cesium-131 Product Line Will Be on Display at the American Society for Radiation Oncology (ASTRO) Convention

RICHLAND, WA --(Marketwired - October 14, 2015) - IsoRay , Inc. ( NYSE MKT : ISR ), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth (505) at the 57 th Annual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place October 18-21, 2015 in San Antonio, Texas at the Henry B. Gonzalez Convention Center. According to IsoRay CEO Dwight Babcock, "The medical community is becoming increasingly aware of the innovative alternatives that our products offer as an important advance over previous brain, lung, prostate and gynecologic cancer treatments."

IsoRay's Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite ®  radiation therapy system give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after tumor removal or when placed directly within the organ. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, providing important benefits for patients in longevity as well as quality of life.

Babcock says "These private dinners provide a forum for peer to peer discussions with other leaders who share their successes in the use of Cesium-131 for some of their most challenging cases. Medical thought leaders recognize the important need for this new powerful weapon in the battle against cancer and Cesium-131 is that solution. A number of new institutions are in the process of licensing Cesium-131 for use within their facility."

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices including the GliaSite® radiation therapy system.

About IsoRay IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com . Join us on Facebook/Isoray. Follow us on Twitter @Isoray .

Safe Harbor Statement

Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems; future demand for IsoRay's existing and planned products; whether revenue and other financial metrics will improve in future periods, whether IsoRay will be able to continue to expand its base beyond prostate cancer; whether sales and use of our products will continue at historic levels or increase; whether additional medical centers will begin using our products; whether awareness of our products in the medical community will continue or increase; whether our sales and marketing efforts will be successful; whether additional studies will be published or presented with favorable outcomes from treatment with our products; whether we will invest in research and development in the future; and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of IsoRay's products, changing levels of demand for IsoRay's current and proposed future products, IsoRay's ability to reduce or maintain expenses while increasing sales, patient results achieved using our products in both the short and long term, success of future research and development activities, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate cancer, IsoRay's ability to successfully manufacture, market and sell its products, IsoRay's ability to manufacture its products in sufficient quantities to meet demand within required delivery time periods while meeting its quality control standards, the success of our sales and marketing efforts, IsoRay's ability to enforce its intellectual property rights, changes in reimbursement rates, changes in laws and regulations applicable to our products, whether additional studies and protocols are released and support the conclusions of past studies and protocols, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in their various forms, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: PCG Advisory Group 535 Fifth Avenue 24th Floor New York, NY 10017 info@pcgadvisory.com (646)-863-6341

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 248

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 485

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

Embrace Pet Insurance Breaks Records in Volunteerism and Giving

Updated Category News Views 317

Embrace Pet Insurance Partners in Charity and Volunteerism Despite facing economic hurdles, charitable contributions across the nation showed remarkable resilience, highlighting the generosity of individuals and businesses alike. Recent reports reveal that charitable donations in the U.S. hit staggering heights, exceeding $557 billion in the last reporting year. Embrace...

Continue Reading
Sony's Innovative OLED Microdisplay Sets New Industry Standards

Updated Category News Views 210

Exploring Sony's Innovative OLED Technology Sony Semiconductor Solutions Corporation is about to change the landscape of augmented reality (AR) with the introduction of its groundbreaking ECX350F. This 0.44-type Full HD OLED Microdisplay is remarkable for its unique features, including the smallest pixel size in the industry and outstanding brightness. This innovation...

Continue Reading
Bascom Palmer Eye Institute Claims Top Spot in Medical Rankings

Updated Category News Views 269

Bascom Palmer Eye Institute's Unrivaled Recognition in 2025 For an impressive 24th consecutive year, Bascom Palmer Eye Institute has been honored as the premier ophthalmology hospital in the United States. This prestigious recognition, detailed in the 2025 U.S. News & World Report "Best Hospitals" rankings, underscores the institute's unwavering commitment to providing...

Continue Reading
Insights on Unusual Options Activity for Alphabet Inc.

Updated Category News Views 269

Unusual Options Activity Analysis for Alphabet Inc. Recent trends indicate that prominent financial players are adopting a bearish stance on Alphabet Inc. Our thorough analysis of options history for Alphabet (GOOGL) highlights 20 unusual trades, emphasizing a notable shift in market sentiment. Understanding Trader Sentiment Upon delving into the trade specifics, our...

Continue Reading
A Critical Juncture for uniQure Amidst Regulatory Challenges

Updated Category News Views 191

uniQure's Recent FDA Feedback The U.S. Food and Drug Administration (FDA) recently provided important insights to uniQure N.V. (NASDAQ: QURE) about its proposed gene therapy for Huntington’s disease. This feedback has led to a noticeable drop in the company’s stock price, reflecting heightened investor concern. Understanding AMT-130 AMT-130 is uniQure’s...

Continue Reading